An Overview of Tuberculosis Chemotherapy - A Literature Review

被引:28
作者
Sarkar, Susmita [1 ]
Suresh, Mavanur R. [1 ]
机构
[1] Univ Alberta, Fac Pharm & Pharmaceut Sci, Edmonton, AB T6G 2N8, Canada
来源
JOURNAL OF PHARMACY AND PHARMACEUTICAL SCIENCES | 2011年 / 14卷 / 02期
关键词
RESISTANT MYCOBACTERIUM-TUBERCULOSIS; ENCAPSULATED ANTITUBERCULAR DRUGS; NECROSIS-FACTOR-ALPHA; VITAMIN-D; PEPTIDE DEFORMYLASE; INTERFERON-GAMMA; MACROPHAGE PHAGOCYTOSIS; PULMONARY TUBERCULOSIS; MICROSPHERE TECHNOLOGY; COST-EFFECTIVENESS;
D O I
10.18433/J33591
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tuberculosis (TB) is a major global health threat. The emergence of human immunodeficiency virus (HIV) and also multi drug resistant (MDR) and extremely drug resistant (XDR)-TB poses a vital challenge to the control of the disease. For the last 50 years, no new anti-TB drug has been discovered. This literature review provides a brief discussion of existing drugs and emerging drug targets, and also of the advantages of incorporating modern drug delivery systems and immune modulators in order to improve the existing treatment regimen in terms of better efficacy, reduced drug administration frequency, shortened period of treatment and reduced drug related toxicity. The investigation for a new drug target is essential to continue the battle against MDR and XDR-TB. However, owing to the enormous cost and time involved in new drug development, improvement of the existing treatment regimen is seen to be a valid alternative.
引用
收藏
页码:148 / 161
页数:14
相关论文
共 110 条
[31]   CHLORPROMAZINE - A DRUG POTENTIALLY USEFUL FOR TREATING MYCOBACTERIAL INFECTIONS [J].
CROWLE, AJ ;
DOUVAS, GS ;
MAY, MH .
CHEMOTHERAPY, 1992, 38 (06) :410-419
[32]   Lung specific stealth liposomes: Stability, biodistribution and toxicity of liposomal antitubercular drugs in mice [J].
Deol, P ;
Khuller, GK .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1997, 1334 (2-3) :161-172
[33]   The Diarylquinoline TMC207 for Multidrug-Resistant Tuberculosis [J].
Diacon, Andreas H. ;
Pym, Alexander ;
Grobusch, Martin ;
Patientia, Ramonde ;
Rustomjee, Roxana ;
Page-Shipp, Liesl ;
Pistorius, Christoffel ;
Krause, Rene ;
Bogoshi, Mampedi ;
Churchyard, Gavin ;
Venter, Amour ;
Allen, Jenny ;
Palomino, Juan Carlos ;
De Marez, Tine ;
van Heeswijk, Rolf P. G. ;
Lounis, Nacer ;
Meyvisch, Paul ;
Verbeeck, Johan ;
Parys, Wim ;
de Beule, Karel ;
Andries, Koen ;
Mc Neeley, David F. .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (23) :2397-2405
[34]   Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis [J].
Dietze, R ;
Teixeira, L ;
Rocha, LMC ;
Palaci, M ;
Johnson, JL ;
Wells, C ;
Rose, L ;
Eisenach, K ;
Ellner, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (07) :1972-1976
[35]   The price of innovation: new estimates of drug development costs [J].
DiMasi, JA ;
Hansen, RW ;
Grabowski, HG .
JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) :151-185
[36]  
DING AH, 1988, J IMMUNOL, V141, P2407
[37]  
Doherty TM, 1998, J IMMUNOL, V160, P5428
[38]  
DOUVAS GS, 1985, INFECT IMMUN, V50, P1
[39]   Mycobacterial shikimate pathway enzymes as targets for drug design [J].
Ducati, R. G. ;
Basso, L. A. ;
Santos, D. S. .
CURRENT DRUG TARGETS, 2007, 8 (03) :423-435
[40]   Global epidemiology of tuberculosis [J].
Dye, C .
LANCET, 2006, 367 (9514) :938-940